POMC is a paradigm for post-translational processing - fundamentally different from alternative splicing. A single mRNA produces ONE precursor protein that is then proteolytically cleaved into multiple bioactive peptides with distinct and sometimes antagonistic functions.
| Peptide | Residues | PRO ID | Function |
|---|---|---|---|
| Signal peptide | 1-26 | - | Secretion |
| NPP | 27-102 | PRO_0000024966 | Unknown |
| Gamma-MSH | 77-87 | PRO_0000024967 | Pigmentation |
| Potential peptide | 105-134 | PRO_0000024968 | Unknown |
| ACTH | 138-176 | PRO_0000024969 | Stimulates cortisol release |
| Alpha-MSH | 138-150 | PRO_0000024970 | Anorexigenic, pigmentation |
| CLIP | 156-176 | PRO_0000024971 | Unknown |
| Beta-LPH | 179-267 | PRO_0000024972 | Lipotropic |
| Gamma-LPH | 179-234 | PRO_0000024973 | Lipotropic |
| Beta-MSH | 217-234 | PRO_0000024974 | Pigmentation |
| Beta-endorphin | 237-267 | PRO_0000024975 | Orexigenic opiate |
| Met-enkephalin | 237-241 | PRO_0000024976 | Opiate |
The key insight is that different tissues produce different peptide combinations:
Processing stops at ACTH level - alpha-MSH is NOT produced here
Intermediate pituitary (minimal in adult humans): MSH peptides
This is the main source of MSH in other species
Hypothalamus (arcuate nucleus): Both alpha-MSH and beta-endorphin
This is critical for GO annotation:
- Alpha-MSH: Anorexigenic (suppresses appetite)
- Beta-endorphin: Orexigenic (stimulates appetite)
Both peptides are produced in the same hypothalamic neurons! The balance between them affects feeding behavior.
| Feature | Alternative Splicing (e.g., BCL2L1) | Polyprotein Processing (POMC) |
|---|---|---|
| Mechanism | Pre-mRNA splicing | Post-translational proteolysis |
| Regulation point | Nucleus (splicing) | ER/Golgi/secretory pathway |
| mRNA products | Multiple distinct mRNAs | Single mRNA |
| Protein products | Different full-length proteins | Multiple peptides from one precursor |
| Tissue specificity | Splice factor expression | Prohormone convertase expression |
| Example enzymes | - | PC1/3, PC2, carboxypeptidases |
Falcon deep research was added as POMC-deep-research-falcon.md. It reinforces
the existing review's main caution: POMC should be treated as a secreted
prohormone precursor whose cleavage products carry distinct receptor-binding and
physiological activities [file:human/POMC/POMC-deep-research-falcon.md
"Pro-opiomelanocortin (POMC) is best curated in GO as a secreted
prohormone precursor that is sorted to regulated secretory granules and
proteolytically processed in a tissue-specific manner to yield multiple
bioactive peptides (ACTH, α/β/γ-MSH, β-endorphin; enkephalin motifs embedded in
the β-LPH/β-endorphin region)."].
The report specifically supports keeping the generic protein-binding annotation
removed and preferring peptide/receptor-specific terms over broad GPCR or
behavior terms [file:human/POMC/POMC-deep-research-falcon.md "Generic protein
binding / identical protein binding: Do not annotate generic binding
(including “identical protein binding”) unless there is direct biochemical
interaction evidence for the relevant molecular entity (precursor vs peptide)."]
and [file:human/POMC/POMC-deep-research-falcon.md "Melanocortin receptor
binding vs generic GPCR binding: Prefer melanocortin receptor binding
terms, with MC2R specificity for ACTH explicitly supported; do not use
generic “GPCR binding” for POMC gene product as a catch-all."].